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Figure 5. Atezolizumab is able to partially block PD-L1 (~70%) in MDA-MB-231 3D 
spheroid colonies at day 10. The level of PD-L1 expression detected by flow cytometry was 
reduced by ~70% when blocked with Atezolizumab in 3D spheroid colonies at day 10 (A). 
Whether Atezolizumab alone or combined with cytokines, detectable PD-L1 expression was 
significantly reduced compared to untreated and cytokine only treated cells. Representative 
flow cytometry plots illustrate the degree of blockade of PD-L1 by Atezolizumab in 3D spheroid 
colonies treated with Atezolizumab alone or combined with cytokines (B). There is a trend 
showing that less PD-L1 is blocked when Atezolizumab is combined with both cytokines. Data 
is presented as mean ± SD, n=3 independent experiments each with 3 technical repeats, 
Kruskal-Wallis followed by Conover Inman multiple comparison test, *P<0.05, **0.01. 











































































Atez + IFNγ 
Atez + TNFα 














Blockade of Programmed Death-Ligand 1 with Atezolizumab in Human 
Breast Cancer 3D Spheroid Colonies Induces Changes in Cell Viability  
Katie Hudson1, Neil Cross1, Nicola Jordan-Mahy1, Rebecca Leyland1 
1Biomolecular Sciences Research Centre, City Campus, Sheffield Hallam University, Howard Street, Sheffield, S1 1WB 
*corresponding author (R.Leyland@shu.ac.uk) 
Introduction 
Methods 
Conclusion and Future Direction 
References 
Results 
Aims and Hypothesis 
• Solid tumours are characterised by a three-dimensional (3D) architecture that provides 
specific survival advantages such as resistance to anti-cancer drugs (Rios de la Rosa et 
al., 2018). 
• The expression of programmed death-ligand 1 (PD-L1) is one such survival mechanism 
employed by tumours to mediate immune evasion, drug resistance and tumour 
progression (Dong et al., 2018). 
• PD-L1 overexpression by cancer cells and immune cells in the tumour microenvironment 
is well known to promote immune evasion, primarily by inhibition of cytotoxic T lymphocyte 
and natural killer (NK) cell effector function (Jiang et al., 2019). However, tumour-intrinsic 
PD-L1 signalling is less established. 
• Monoclonal antibodies targeting PD-L1 have demonstrated significant anti-tumour immune 
responses in select patients with advanced cancers (Yang and Hu, 2019) 
• Better mimicking of the 3D architecture of solid tumours by utilising 3D cell culture could 
provide an environment more representative of in vivo human tumours for the 
investigation of PD-L1 in relation to its tumour-intrinsic role, interaction with PD-1 on 
immune cells and response to treatment. 
• This research aimed to: 1) determine whether PD-L1 expression by human breast cancer 
cells altered in 3D cell culture compared to 2D cell culture and 2) investigate the effects of 
PD-L1 blockade ± cytokine modulation on human breast cancer cell viability in a 3D cell 
culture system. 
• It was hypothesised that PD-L1 expression would alter in 3D cell culture compared to 2D 
cell culture and that PD-L1 blockade ± cytokine modulation would promote cancer cell 
death in human breast cancer cells expressing moderate to high levels of PD-L1 following 
growth in a 3D cell culture system. 
Cell Culture  Human breast cancer cells (MDA-MB-231 and MCF-7) were cultured in RPMI 
media supplemented with 10% FBS and 1% penicillin-streptomycin. Cells were cultured in 2D 
monolayer and 3D alginate hydrogel beads (Figure 1). Cells were purchased from ATCC, 









Figure 1. A schematic diagram of the work flow applied to human breast cancer cells to generate 2D and 3D cultures 
for assessment using fluorescent microscopy, qPCR and flow cytometry. For 3D cell culture, alginate hydrogel beads 
were utilised which facilitate the formation of spheroid colonies that display heterogeneous population of cells resembling that 
found in the tumour microenvironment. Spheroid colonies generated were harvested for downstream analysis at day 3, 6 and 
10. 2D-cultured cells were harvested 3 days after seeding at day 3, 6 and 10. Appropriate controls and gating strategies were 
carried out for each experiment. 
 
Cell Viability in 3D Culture At day 3, 6 and 10 alginate hydrogel beads for each cell line 
were harvested from culture, placed in a 96-well plate and labelled with Hoechst 33342 (10 
µg/mL) and propidium iodide (PI) (10 µg/mL). Images were captured using cellSense 
Software on an Olympus IX81 microscope.  
PD-L1 Expression Total RNA from 2D- and 3D- cultured breast cancer cells was extracted, 
quantified and converted to cDNA for measuring mRNA levels of PD-L1 using TaqMan qPCR. 
Cell surface PD-L1 expression was assessed using flow cytometry by staining with 
fluorescently labelled anti-human PD-L1 and matched isotype control. Data was acquired 
using a BD FACSCalibur or Beckman Coulter CytoFLEX and analysed using FlowJo 
software. The median fluorescent intensity (MFI) was normalised relative to the isotype 
control.  
Atezolizumab Treatment Cells grown in 3D cell culture were treated with 10 nM 
Atezolizumab ± IFNγ and/or TNFα over a time course of 10 days (Figure 2 A and B). Cells 
were harvested and assessed by flow cytometry for cell surface PD-L1 expression. 
Simultaneously, cells were stained with Annexin V and PI to assess cancer cell death using 
flow cytometry. Some cells were treated with IFNγ (0.5 ng/ml) and TNFα (5 ng/ml) for 48 hr 
before Atezolizumab treatment to modulate PD-L1 expression.  
Figure 2. Timeline of Atezolizumab 
treatment strategies ± IFNγ and/or 
TNFα for 3D-cultured breast cancer 
cells. (A) 3D cultures were treated with 
Atezolizumab every 3-4 days from day 
0. Following this treatment strategy, 3D 
cultures were harvested for analysis at 
day 10. (B) 3D cultures were treated 
with IFNγ and/or TNFα 48 hr prior to 
dosing with Atezolizumab at day 10 for 
1 hr before harvesting for analysis. 
Appropriate controls were utilised in 
each experiment. 
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Figure 3. Human breast cancer cell spheroid colonies formed in alginate hydrogel beads exhibit significantly altered PD-L1 expression in 
comparison to their 2D counterparts at mRNA and protein level. Fluorescent images obtained by Hoechst 33342/PI staining of whole intact alginate beads 
at day 10 are shown for each breast cancer cell line; MDA-MB-231 (A) and MCF-7 (F). Scale bar represents 500 μm. The closer images of individual spheroid 
colonies in the white boxes represent spheroids within the alginate bead that have a diameter of 100-200 μm for each cell line. MDA-MB-231 cancer cells 
grown in 3D display a significant decrease in the level of PD-L1 (CD274) mRNA (B) and protein (C, D, E) at day 3, 6 and 10 compared to when grown in 2D. 
Similarly, MCF-7 cancer cells in 3D exhibit a significant decrease in PD-L1 (CD274) mRNA at day 3, 6 and 10 (G). Interestingly, MCF-7 cancer cells show a 
significant increase in the frequency of cells expressing PD-L1 expression at each time point investigated in 3D in comparison to their 2D counterparts (H, I), 
but display no change in the level of PD-L1 at the protein level (J). Data is presented as mean ± SD, n=3 independent experiments each with 3 technical 
repeats, Kruskal-Wallis followed by Conover Inman multiple comparison test, *P<0.05, **0.01, ***0.001, ****P<0.0001.  
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PD-L1 blockade in MDA-MB-231 3D spheroid coloniesA B A B 
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Figure 4. Gating strategies for flow cytometric analysis of 
cell surface PD-L1 and cell death via Annexin V/PI 
staining. For all experiments cells of interest (A) and single 
cell populations (B) were gated. Single colour controls for 
Annexin V/PI staining were used to gate for live (AV-/PI-), 
early apoptotic (AV+/PI-), late apoptotic (AV+/PI+) and 
necrotic (AV-/PI+) cells (C). Live cell gating was performed for 
assessing PD-L1 expression by staining with PI. Isotype 
controls for untreated and treated cells were prepared and 




































































































































































































































Atez Atez + IFNγ Atez + TNFα Atez + Combo 
TNFα IFNγ Combo 
D Figure 6. Atezolizumab alone and in combination with cytokines induces cell death 
in MDA-MB-231 3D spheroid colonies at day 10. The percentage of non-viable cells 
(AV+/PI-, AV+/PI+, AV-/PI+) at day 10 shows the same trend across each experiment (A). 
Atezolizumab alone and/or combined with cytokines induces cell death in MDA-MB-231 
3D spheroid colonies at day 10. A representative graph of experiment 1 demonstrates the 
percentage of live, early apoptotic, late apoptotic and necrotic cells for untreated and 
treated 3D spheroid colonies at day 10 (B). Atezolizumab alone and cytokines alone 
induce cell death in 3D spheroid colonies at day 10 and when Atezolizumab is combined 
with cytokines there is a synergistic effect inducing cell death in 3D spheroid colonies; 
which is significant when Atezolizumab is combined with both cytokines (C, D). Data is 
presented as mean ± SD, n=3 independent experiments each with 3 technical repeats, 
Kruskal-Wallis followed by Conover Inman multiple comparison test, *P<0.05, **0.01, 
***0.001, ****P<0.0001.  
Figure 7. Preliminary data suggests that low PD-L1 
expressing MCF-7 cells grown in 3D spheroid colonies show 
a similar phenotype to high PD-L1 expressing MDA-MB-231 
cells in response to Atezolizumab ± cytokines at day 10. 
The percentage of necrotic cells (AV-/PI+) at day 10 shows the 
same trend across each experiment (A). Atezolizumab alone 
and/or combined with cytokines induces necrosis in MCF-7 3D 
spheroid colonies. A representative graph of experiment 2 
displays the percentage of live, early apoptotic, late apoptotic and 
necrotic cells for untreated and treated 3D spheroid colonies at 
day 10 (B). Data is presented as mean ± SD, n=2 independent 












































































• PD-L1 mRNA and protein levels are significantly altered in breast cancer cells in 3D cell culture compared to their 2D 
counterparts.  
• 10 nM Atezolizumab blocks ~ 70% PD-L1 in 3D spheroid colonies . 
• Atezolizumab treatment over a period of 10 days in 3D spheroid colonies induces increased cell death of MDA-MB-
231 and MCF-7 breast cancer cells which is significantly enhanced via cytokine modulation. 
• Future work will assess PD-L1 knockdown in MDA-MB-231 breast cancer cells cultured in 2D and 3D cell culture. 
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